Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia

Next Previous
X
Search
Trial Profile

BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Prednisolone; Vincristine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BLAM

    • Most Recent Events

    • 15 Jun 2023 Results of an analysis of the final endpoint at 14 Feb 2023; n=30 presented at the 28th Congress of the European Haematology Association
    • 14 Dec 2021 Interim results (n=30 ) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 06 Nov 2019 Results assessing response to therapy of the first 10 patients enrolled on this study, released in 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top